TPST:NASDAQTempest Therapeutics, Inc. Analysis

Technical outlook: TPST trades at $0.86, just above the computed support of $0.84 and far below its 52‑week high of $12.23, indicating a deep discount. All three moving averages (20‑day SMA ≈ 0.96, 50‑day SMA ≈ 1.19, 200‑day SMA ≈ 3.14) sit well above the current price, confirming a bearish trend, yet the RSI of 28.8 places the stock in oversold territory and the MACD histogram has turned slightly positive, hinting at a potential short‑term bounce.
Fundamental & catalyst outlook: The company remains pre‑revenue with zero sales, negative EBITDA of $‑20.9 M, and a debt‑to‑equity ratio over 950, making the current price‑to‑book of 15 appear high for a cash‑burning biotech. Liquidity is tight ($1.8 M cash vs $7.85 M debt). However, recent material news – a next‑generation in‑vivo CAR‑T pipeline slated for a Q4 2026 clinical start and the addition of two independent directors – provides a meaningful near‑term catalyst, while the Roche collaboration adds credibility to the long‑term value proposition.